Is the transfer of patients with ST-segment elevation myocardial infarction (STEMI) to an invasive-treatment center (ITC) for primary angioplasty (percutaneous coronary intervention [PCI]) more effective than on-site fibrinolysis for reducing all-cause mortality, reinfarction, or stroke?
D e s i g n
Randomized (allocation concealed*), blinded (outcome assessors),* controlled trial with 30-day follow-up (Danish trial in Acute Myocardial Infarction-2 [DANAMI-2]).
S e t t i n g
24 referral hospitals (RHs) and 5 ITCs in Denmark.
P a t i e n t s
1572 patients ≥ 18 years age (median age 63 y, 73% men) who had STEMI. Exclusion criteria included contraindication to fibrinolysis and left bundle-branch block. Followup was 100%.
I n t e r v e n t i o n
Patients were stratified by hospital and allocated to PCI (n = 567 at RHs and 223 at ITCs) or fibrinolysis (n = 562 at RHs and 220 at ITCs). Patients in the PCI group received heparin, 10 000 U plus aspirin, 300 mg intravenously with immediate transportation to a catheterization laboratory for acute angiography, angioplasty, and primary stenting. Fibrinolytic therapy comprised accelerated treatment with alteplase and was administered by ambulance crews.
M a i n o u t c o m e m e a s u r e
Composite endpoint of all-cause mortality, clinical reinfarction, or disabling stroke.
M a i n r e s u l t s
Analysis was by intention to treat. 96% of patients allocated to PCI at RHs were transferred to an ITC ≤ 2 hours after admission. Among all patients combined and among patients randomized at RHs or ITCs separately, the rate of the composite endpoint was lower in the PCI group than in the fibrinolysis group (Table) .
C o n c l u s i o n
The transfer of patients who have had myocardial infarction with ST-segment elevation to an invasive-treatment center for primary percutaneous coronary intervention was more effective than on-site fibrinolysis for reducing all-cause mortality, reinfarction, or stroke. T 
C o m m e n t a r y
Primary PCI offers advantages over fibrinolytic therapy when done promptly in excellent PCI centers (1). However, the conclusion from DANAMI-2 that hospitals without PCI capability must withhold fibrinolytic therapy and transfer patients for primary PCI because of the reduction in the composite endpoint of death, reinfarction, or disabling stroke compared with on-site fibrinolytic therapy deserves further scrutiny because of study design. The composite endpoint was driven by the reduction in reinfarction rates with primary PCI. Trends for mortality and disabling stroke reduction with PCI were statistically insignificant. It is important to note that in the fibrinolysis group, rescue PCI was only used in 2% of patients and reinfarction was treated with repeated fibrinolysis instead of angioplasty. With a 30-day mortality rate of 24% after reinfarction, approximately 7 excess deaths occurred in the fibrinolysis group because of this complication. The use of low-molecular-weight heparin instead of unfractionated heparin and a more liberal policy of permitting angioplasty to treat recurrent ischemia in the fibrinolysis group probably would have decreased reinfarction rates and equalized mortality rates. In addition, the stroke rate in the fibrinolysis group was higher than noted in previous fibrinolysis megatrials: Whether the higher-than-currently-recommended unfractionated heparin dosing used in this study or the repeated fibrinolysis infusion in 26 patients contributed to this excess was not discussed. In transfer patients, time to PCI was only 90 minutes because of a superbly organized national MI triage system, compared with 185 minutes in the United States in 2002 (2) .
Unless local emergency transport programs can deliver patients to PCI centers within the times observed in this study, fibrinolytic therapy should be the preferred treatment strategy for patients who present to hospitals without PCI capability. In such settings, emergency transfer to PCI centers should be reserved for moderate-and high-risk patients in whom reperfusion fails or for those who develop recurrent ischemia.
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